Discovery of highly selective brain-penetrant vasopressin 1a antagonists for the potential treatment of autism via a chemogenomic and scaffold hopping approach.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2015-02-18

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1021/jm501745fPMID 25654260
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The role of ligand efficiency metrics in drug discovery

  2014cited by this paper
• Pharmacokinetics and metabolism of SRX246: a potent and selective vasopressin 1a antagonist.

  2013cited by this paper
• A novel V1a receptor antagonist blocks vasopressin-induced changes in the CNS response to emotional stimuli: an fMRI study

  2013cited by this paper
• Synthesis and evaluation of potent and selective human V1a receptor antagonists as potential ligands for PET or SPECT imaging.

  2012cited by this paper
• Optimisation of pharmacokinetic properties to afford an orally bioavailable and selective V1A receptor antagonist.

  2011cited by this paper
• The discovery of novel 8-azabicyclo[3.2.1]octan-3-yl)-3-(4-chlorophenyl) propanamides as vasopressin V1A receptor antagonists.

  2011cited by this paper
• Discovery of PF-184563, a potent and selective V1a antagonist for the treatment of dysmenorrhoea. The influence of compound flexibility on microsomal stability.

  2011cited by this paper
• Modulation of the vasopressin system for the treatment of CNS diseases.

  2010cited by this paper
• The challenge of translation in social neuroscience: a review of oxytocin, vasopressin, and affiliative behavior.

  2010cited by this paper
• Vasopressin Modulates Medial Prefrontal Cortex–Amygdala Circuitry during Emotion Processing in Humans

  2010cited by this paper
• Characterization of the V1a antagonist, JNJ-17308616, in rodent models of anxiety-like behavior

  2009cited by this paper
• Non-peptide arginine-vasopressin antagonists: the vaptans.

  2008cited by this paper
• Me-Talnetant and Osanetant Interact within Overlapping but Not Identical Binding Pockets in the Human Tachykinin Neurokinin 3 Receptor Transmembrane Domains

  2008cited by this paper
• Imaging the neural circuitry and chemical control of aggressive motivation

  2008cited by this paper
• Orally active vasopressin V1a receptor antagonist, SRX251, selectively blocks aggressive behavior.

  2006cited by this paper
• An Automated System for the Analysis of G Protein-Coupled Receptor Transmembrane Binding Pockets: Alignment, Receptor-Based Pharmacophores, and Their Application

  2005cited by this paper
• UniProt: the Universal Protein knowledgebase

  2004cited by this paper
• The effects of vasopressin on human facial responses related to social communication.

  2004cited by this paper
• Profound Impairment in Social Recognition and Reduction in Anxiety-Like Behavior in Vasopressin V1a Receptor Knockout Mice

  2004cited by this paper
• High-Throughput Modeling of Human G-Protein Coupled Receptors: Amino Acid Sequence Alignment, Three-Dimensional Model Building, and Receptor Library Screening

  2004cited by this paper
• Forced swimming triggers vasopressin release within the amygdala to modulate stress‐coping strategies in rats

  2002cited by this paper
• Vasopressin into the preoptic area increases grooming behavior in mice.

  2001cited by this paper
• Localization of Vasopressin (V1a) Receptor Binding and mRNA in the Rhesus Monkey Brain

  1999cited by this paper
• New chemical descriptors relevant for the design of biologically active peptides. A multivariate characterization of 87 amino acids.

  1998cited by this paper
• Spiro-substituted piperidines as neurokinin receptor antagonists. II. Syntheses and NK2 receptor-antagonistic activities of N-[2-aryl-4-(spiro-substituted piperidin-1'-yl)butyl]carboxamides.

  1998cited by this paper
• ASYMMETRIC SYNTHESIS OF (R)- AND (S)-2-PYRROLIDINEMETHANESULFONIC ACID

  1997cited by this paper
• Septal vasopressin modulates anxiety-related behaviour in rats.

  1996cited by this paper
• Extrapituitary expression of the rat V1b vasopressin receptor gene.

  1995cited by this paper
• Effect of SR-49059, a vasopressin V1a antagonist, on human vascular smooth muscle cells.

  1995cited by this paper
• Cellular localization of vasopressin V1a receptor messenger ribonucleic acid in adult male rat brain, pineal, and brain vasculature.

  1994cited by this paper
• Biochemical and pharmacological properties of SR 49059, a new, potent, nonpeptide antagonist of rat and human vasopressin V1a receptors.

  1993cited by this paper
• Structure and expression of a human oxytocin receptor

  1992cited by this paper
• Distribution of V1a and V2 vasopressin receptor messenger ribonucleic acids in rat liver, kidney, pituitary and brain.

  1992cited by this paper
• Localization of high-affinity binding sites for oxytocin and vasopressin in the human brain. An autoradiographic study.

  1991cited by this paper
• Novel 5-HT3 antagonists. Indole oxadiazoles.

  1991cited by this paper
• Vasopressin‐induced Grooming and Scratching Behavior in Mice

  1988cited by this paper
• Unusual site of electrophilic attack on indole and carbazole

  1976cited by this paper

• Non-peptidic natural products that target and modulate oxytocin and arginine vasopressin receptors: Opportunities and challenges.

  2025cites this paper
• Vasopressin and oxytocin receptors in GtoPdb v.2025.3

  2025cites this paper
• Synthesis of Spirocyclic Phthalans via Ru-Catalyzed [2 + 2 + 2] Cycloaddition of 1,6-Diynes with Ex-Situ Generated Acetylene.

  2025cites this paper
• Discovery and Characterization of RGH-122, a Potent, Selective, and Orally Bioavailable V1a Receptor Antagonist.

  2024cites this paper
• Development of dual V1a/V2 antagonists containing triazolobenzazepine scaffold.

  2024cites this paper
• Discovery and evaluation of a novel 18F-labeled vasopressin 1a receptor PET ligand with peripheral binding specificity

  2024cites this paper
• Oxytocin and vasopressin signaling in health and disease.

  2024cites this paper
• Vasopressin V1a receptor and oxytocin receptor regulate murine sperm motility differently

  2023influential citation
• A condition-tuned unorthodox approach to indole-3-carboxylic acids and anthranilic acids via carbon atom translocation.

  2023cites this paper
• Vasopressin receptor antagonists: a patent summary (2018-2022)

  2023cites this paper
• Exploring isofunctional molecules: Design of a benchmark and evaluation of prediction performance

  2023cites this paper
• Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder

  2022cites this paper
• Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program

  2022cites this paper
• Synthesis and Characterization of New V1A Antagonist Compounds: The Separation of Four Atropisomeric Stereoisomers.

  2021cites this paper
• Vasopressin-stimulated ORAI1 expression and store-operated Ca2+ entry in aortic smooth muscle cells

  2021cites this paper
• The Biology of Vasopressin

  2021cites this paper
• Classification models and SAR analysis on CysLT1 receptor antagonists using machine learning algorithms

  2021cites this paper
• Development of a Triazolobenzodiazepine-Based PET Probe for Subtype-Selective Vasopressin 1A Receptor Imaging

  2021cites this paper
• Modern Tools and Techniques in Computer-Aided Drug Design

  2021cites this paper
• Exploring the Effect of Structure-Based Scaffold Hopping on the Inhibition of Coxsackievirus A24v Transduction by Pentavalent N-Acetylneuraminic Acid Conjugates

  2021cites this paper
• Diastereoselective Synthesis of Spirocyclic Ether from ortho ‐Carbonylarylacetylenols via Silver‐Catalyzed Cyclization under Acidic Conditions

  2021cites this paper
• Discovery of Balovaptan, a Vasopressin 1a Receptor Antagonist for the Treatment of Autism Spectrum Disorder.

  2020cites this paper
• Spirocyclic Scaffolds in Medicinal Chemistry.

  2020cites this paper
• Discovery of New Heterocyclic Ring Systems as Novel and Potent V1A Receptor Antagonists.

  2020cites this paper
• New V1a receptor antagonist. Part 1. Synthesis and SAR development of urea derivatives.

  2020cites this paper
• New V1a receptor antagonist. Part 2. Identification and optimization of triazolobenzazepines.

  2020cites this paper
• Do animal models hold value in Autism spectrum disorder (ASD) drug discovery?

  2019cites this paper
• Vasopressin and oxytocin receptors (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database

  2019cites this paper
• Adults with autism spectrum disorder: Updated considerations for healthcare providers

  2019cites this paper
• A phase 2 clinical trial of a vasopressin V1a receptor antagonist shows improved adaptive behaviors in men with autism spectrum disorder

  2019cites this paper
• A randomized placebo-controlled pilot trial shows that intranasal vasopressin improves social deficits in children with autism

  2019cites this paper
• Acylative Coupling of Amine and Indole Using Chloroform as a Carbonyl Group

  2018cites this paper
• High-yielding 18F radiosynthesis of a novel oxytocin receptor tracer, a probe for nose-to-brain oxytocin uptake in vivo

  2018cites this paper
• Building bridges for highly selective, potent and stable oxytocin and vasopressin analogs.

  2018cites this paper
• The in silico drug discovery toolbox: applications in lead discovery and optimization.

  2017cites this paper
• Vasopressin and Related Peptides; Potential Value in Diagnosis, Prognosis and Treatment of Clinical Disorders.

  2017cites this paper
• Saturated Heterocycles with Applications in Medicinal Chemistry

  2017cites this paper
• Targets for Drug Therapy for Autism Spectrum Disorder: Challenges and Future Directions.

  2017cites this paper
• Recent Advances in Scaffold Hopping.

  2017cites this paper
• Friedel-Crafts Fluoroacetylation of Indoles with Fluorinated Acetic Acids for the Synthesis of Fluoromethyl Indol-3-yl Ketones under Catalyst- and Additive-Free Conditions.

  2016cites this paper
• Identification of novel small-molecule inhibitors targeting menin-MLL interaction, repurposing the antidiarrheal loperamide.

  2016cites this paper
• A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder

  2016cites this paper
• Intriguing possibilities and beneficial aspects of transporter-conscious drug design.

  2015cites this paper